Treatment of sarcoidosis - From a basic science point of view

Research output: Contribution to journalArticlepeer-review

91 Scopus citations


Progress in our understanding of the scientific basis of granulomatous inflammation in sarcoidosis provides a framework for enlightened treatment decisions. Current evidence supports the concept that the pathogenesis of sarcoidosis involves a highly polarized T-helper 1 (Th1) immune response to pathogenic tissue antigens. Conventional treatment is focused on attenuating granuloma formation with antimalarial drugs that inhibit antigen presentation or with nonspecific anti-inflammatory agents such as glucocorticosteroids, methotrexate, or azathioprine. Anti-tumour necrosis factor (TNF)-α agents such as pentoxifylline, thalidomide, etanercept and remicade, have recently shown some successes in sarcoidosis. Designing future therapies depends on improved knowledge of the critical immunological processes operative in different stages of disease.

Original languageEnglish (US)
Pages (from-to)31-40
Number of pages10
JournalJournal of Internal Medicine
Issue number1
StatePublished - 2003


  • Immunosuppression
  • Sarcoidosis
  • T-helper 1 immunity
  • Treatment
  • Tumour necrosis factor

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Treatment of sarcoidosis - From a basic science point of view'. Together they form a unique fingerprint.

Cite this